Martínez-Jañez, N. http://orcid.org/0000-0002-0436-0906
Ezquerra, M. Bellet http://orcid.org/0000-0001-8859-8307
Manso Sanchez, L. M. http://orcid.org/0000-0002-1683-550X
Carrasco, F. Henao http://orcid.org/0000-0003-3819-9572
Torres, A. Anton http://orcid.org/0000-0002-9159-4988
Morales, S. http://orcid.org/0000-0001-7445-4193
Ortega, P. Tolosa http://orcid.org/0000-0002-3747-4766
Gil, V. L. Obadia http://orcid.org/0000-0001-9886-2626
Sampedro, T.
Conejero, R. Andrés http://orcid.org/0000-0003-4315-415X
Calvo-Martinez, L.
Galve-Calvo, E. http://orcid.org/0000-0003-4204-5736
López, R. http://orcid.org/0000-0003-1315-655X
de la Pena, F. Ayala http://orcid.org/0000-0001-6311-920X
Lopez-Tarruella, S. http://orcid.org/0000-0002-2606-9538
de Araguiz, B. A. Hernando Fernandez http://orcid.org/0000-0001-5650-3502
Ruiz, L. Boronat
Cardenas, T. Martos
Chacon, J. I.
Antón, F. Moreno http://orcid.org/0000-0001-8933-0687
Funding for this research was provided by:
Universidad Complutense de Madrid
Article History
Received: 8 November 2023
Accepted: 7 February 2024
First Online: 1 April 2024
Declarations
:
: N. Martínez-Jañez: Advisory board from Roche, Daiichi Sankyo AstraZeneca, Pfizer, Novartis and Eisai.L. M. Manso Sanchez: LM reports of personal fees for advisory boards from Pfizer, travel and accommodation from Pfizer and, for speaker engagements from Pfizer.A. Anton Torres: Financial Interests: AstraZeneca-Daiichi Sankyo, Advisory Board, Personal. AstraZeneca-Daiichi-Sankyo, Invited Speaker, Personal. Eli Lilly, Expert Testimony, Personal. Eli Lilly, Advisory Board, Personal. Eli Lilly, Invited Speaker, Personal. Gilead, Advisory Board, Personal. Pfizer, Expert Testimony, Personal. Seagen, Invited Speaker, Personal.P. Tolosa Ortega: Consultant or Advisory Role: AstraZeneca, Daiichi Sankyo, Novartis and Seagen. Speaking: Pfizer, Novartis, Lilly, AstraZeneca, Daiichi-Sankyo, Gilead and Seagen. Research Funding: Novartis.R. Andrés Conejero: Speaker and have received help to attend conferences from Pfizer in the last two years.E. Galve-Calvo: Financial Interests: AstraZeneca, Invited Speaker, Personal. AstraZeneca, Expert Testimony, Personal. AstraZeneca, Advisory Board, Personal. Daiichi Sankyo, Expert Testimony, Personal. Daiichi Sankyo, Invited Speaker, Personal. Daiichi Sankyo, Advisory Board, Personal. Eisai, Expert Testimony, Personal. Gilead, Invited Speaker, Personal. Gilead, Expert Testimony, Personal. Gilead, Advisory Board, Personal. Novartis, Expert Testimony, Personal. Pfizer, Invited Speaker, Personal. Pfizer, Expert Testimony, Personal. Pfizer, Advisory Board, Personal. Pierre Fabre, Expert Testimony, Personal. Roche, Expert Testimony, Personal. Other: Pfizer, Other, Travel accommodation.R. López: Advisory role: Roche, AstraZeneca, Merck, MSD, Bayer, BMS, Novartis, Janssen, Lilly, Pfizer, Leo, Rovi, Daiichi Sankyo, Seattle Genetics. Speaker’s fee: Roche, Novartis, Pharmamar. Research support: Roche, Merck. Co-founder and shareholder: Nasasbiotech, Diversa Technologies.F. Ayala de la Pena: FAP has received speaker honoraria from AstraZeneca, Novartis, Lilly, Sanofi, Daiichi Sankyo, Celgene, Eisai and Pierre Fabre; has received consultant honoraria from Pfizer, Seagen and Roche; has received educational and research funding from MSD and Daiichi Sankyo.S. Lopez-Tarruella: Financial Interests AstraZeneca, Advisory Board, Personal Daiichi Sankyo, Advisory Board, Personal Gebro Pharma, Advisory Board, Personal Gilead, Advisory Board, Personal GSK, Advisory Board, Personal Lilly, Advisory Board, Personal Lilly, Invited Speaker, Personal Menarini_Stemline, Advisory Board, Personal MSD, Advisory Board, Personal Novartis, Advisory Board, Personal Pfizer, Advisory Board, Personal Pierre Fabre, Advisory Board, Personal Roche, Advisory Board, Personal Seagen, Advisory Board, Personal Veracyte, Advisory Board, Personal Non-Financial Interests GEICAM, Member of Board of Directors SEOM, Member of Board of Director.B.A. Hernando Fernandez de Aranguiz: Fees for consultancy or presentations and/or support for travel to conferences from Seagen, Pierre Fabre, Lilly, GSK, MSD, Tesaro, Pharmamar and Pfizer in the last 5 years.F. Moreno Anton: Consultancy/speaker fees from Novartis, Roche, Pfizer, AstraZeneca, Daiichi Sankyo, Gilead, Exact Sciences, Seagen. Institution research funding from Pfizer. Travel support from Pfizer, Pierre Fabre.